Related Experiment Video
Updated: Jul 25, 2026
08:50
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
23.9K
Bendamustine-induced nephrogenic diabetes insipidus - A case report.
Audrey Desjardins1, Viviane Le-Nguyen1, Léa Turgeon-Mallette1
1Faculty of Pharmacy, Université de Montréal, Montreal, Canada.
Summary
Bendamustine, used in lymphoma treatment, can cause partial nephrogenic diabetes insipidus. This condition, a rare side effect of the BeEAM protocol, resolved with supportive care.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- High-dose chemoimmunotherapy with autologous hematopoietic cell transplantation (HCT) is standard for relapsed/refractory lymphoma.
- Bendamustine is a key component of the BeEAM conditioning protocol prior to HCT.
- Optimal salvage regimens for lymphoma remain under investigation due to variable toxicity.
Observation:
- A case of partial nephrogenic diabetes insipidus is reported following bendamustine administration.
- The patient received bendamustine as part of the BeEAM protocol for conditioning therapy.
- This represents a rare adverse event associated with bendamustine treatment.
Findings:
- Partial nephrogenic diabetes insipidus developed after bendamustine-based conditioning therapy.
- Management involved parenteral fluids and intranasal desmopressin.
- The condition demonstrated spontaneous resolution.
Implications:
- Highlights a rare but significant side effect of bendamustine, impacting electrolyte balance and water homeostasis.
- Underscores the importance of monitoring renal function and fluid balance in patients undergoing HCT with bendamustine.
- Contributes to the understanding of bendamustine-induced toxicities and informs clinical management strategies.
More Related Videos
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:29Diabetes Insipidus I: Introduction
Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...
01:22Diabetes Insipidus II: Pathophysiology
Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...